Weekly Recap: ABS-201 Phase 2 STORYLINE and Needham $11 Buy

Absci Corporation (NASDAQ:ABSI) is advancing ABS-201 into a global Phase 2 STORYLINE trial for endometriosis targeting ~150 patients with a mid-2027 start pending clearance, while Needham maintains a Buy rating and $11 price target on NASDAQ:ABSI.Previous Week RecapThis is an AI-generated summary a…